Literature DB >> 15655272

Effects of statins on circulating oxidized low-density lipoprotein in patients with hypercholesterolemia.

Shigenobu Inami1, Kentaro Okamatsu, Masamichi Takano, Gen Takagi, Shunta Sakai, Junko Sano, Kyoichi Mizuno.   

Abstract

UNLABELLED: Recently, it has been reported that circulating oxidized low-density lipoprotein (Ox-LDL) might be a pivotal indicator for coronary artery disease and the severity of acute coronary syndromes. The purpose of this study was to investigate the effects of statins on Ox-LDL in patients with hypercholesterolemia. Sixteen patients with hypercholesterolemia were randomly assigned to 2 groups, one received 10 mg of pravastatin (n = 8) and the other received 20 mg of fluvastatin (n = 8). The plasma level of Ox-LDL was measured using a newly developed sandwich enzyme-linked immunosorbent assay (ELISA) method. There were no differences between the two groups in Ox-LDL, total cholesterol (TC), or LDL cholesterol (LDL-C) at the baseline. The reduction in Ox-LDL in the fluvastatin group was significantly higher than that in the pravastatin group (47.5% versus 25.2%, P = 0.033). The reductions in TC and LDL-C did not differ between the two groups.
CONCLUSION: The present study has shown for the first time that the level of circulating Ox-LDL was significantly decreased by treatment with statins. In addition, the lowering effect of statins on the circulating Ox-LDL was independent of their lipid-lowering effect. Fluvastatin was more effective than pravastatin with regard to decreasing the circulating Ox-LDL.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15655272     DOI: 10.1536/jhj.45.969

Source DB:  PubMed          Journal:  Jpn Heart J        ISSN: 0021-4868


  6 in total

1.  Antioxidant effects of simvastatin in primary and secondary prevention of coronary heart disease.

Authors:  A Tavridou; A Efthimiadis; I Efthimiadis; H Paschalidou
Journal:  Eur J Clin Pharmacol       Date:  2006-04-21       Impact factor: 2.953

2.  Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial.

Authors:  Seyyed M R Parizadeh; Mahmoud R Azarpazhooh; Mohsen Moohebati; Mohsen Nematy; Majid Ghayour-Mobarhan; Shima Tavallaie; Amir A Rahsepar; Maral Amini; Amirhossein Sahebkar; Maryam Mohammadi; Gordon A A Ferns
Journal:  Lipids       Date:  2011-01-05       Impact factor: 1.880

3.  Reduced oxidized LDL in T2D plaques is associated with a greater statin usage but not with future cardiovascular events.

Authors:  Pratibha Singh; Isabel Goncalves; Christoffer Tengryd; Mihaela Nitulescu; Ana F Persson; Fong To; Eva Bengtsson; Petr Volkov; Marju Orho-Melander; Jan Nilsson; Andreas Edsfeldt
Journal:  Cardiovasc Diabetol       Date:  2020-12-14       Impact factor: 9.951

Review 4.  The Effects of Statin Therapy on Oxidized LDL and Its Antibodies: A Systematic Review and Meta-Analysis.

Authors:  Tannaz Jamialahmadi; Fatemeh Baratzadeh; Željko Reiner; Massimo R Mannarino; Vladimiro Cardenia; Luis E Simental-Mendía; Matteo Pirro; Gerald F Watts; Amirhossein Sahebkar
Journal:  Oxid Med Cell Longev       Date:  2022-08-01       Impact factor: 7.310

5.  Direct free radical scavenging effects of water-soluble HMG-CoA reductase inhibitors.

Authors:  Ryohei Umeda; Hiroki Takanari; Kazue Ogata; Shigekiyo Matsumoto; Takaaki Kitano; Katsushige Ono; Osamu Tokumaru
Journal:  J Clin Biochem Nutr       Date:  2018-08-08       Impact factor: 3.114

6.  The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Tannaz Jamialahmadi; Fatemeh Baratzadeh; Željko Reiner; Luis E Simental-Mendía; Suowen Xu; Andrey V Susekov; Raul D Santos; Amirhossein Sahebkar
Journal:  Mediators Inflamm       Date:  2021-09-04       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.